Research programme: myelosuppression therapy - BiotheraAlternative Names: Imprime WGP
Latest Information Update: 18 Sep 2006
At a glance
- Originator Biothera
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Myelosuppression
Most Recent Events
- 18 Sep 2006 Biothera has been awarded a SBIR grant for the treatment of acute radiation exposure with Imprime WGP™
- 25 Oct 2005 Preclinical trials in Myelosuppression in USA (PO)